The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib Promising for Adults with AS

Tofacitinib Promising for Adults with AS

November 24, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Tofacitinib may be an effective treatment for patients with active ankylosing spondylitis (AS), according to a phase 3 study from Deodhar et al. presented in a late-breaking abstract session during ACR Convergence 2020.1

You Might Also Like
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes
Also By This Author
  • Abx464 Enters Phase 2 Clinical Trials for RA in Europe

The study evaluated the efficacy and safety of tofacitinib in adults with AS (N=269), which was documented with centrally read radiographs. To participate, patients had to meet modified New York Criteria and have an inadequate response or intolerance to at least two non-steroidal anti-inflammatory drugs (NSAIDs). The study’s initial 16 weeks included a double-blind phase during which patients were randomized in a 1:1 ratio to receive either 5 mg of tofacitinib twice daily or placebo. After week 16, all patients received open-label tofacitinib until week 48.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Of the randomized patients, 133 received tofacitinib and 136 received placebo. Additionally, 77% of patients were naive to biologic disease-modified anti-rheumatic drugs (DMARDs). The patients’ mean age was 41, with the majority of participants being white (80.5%) and male (87%) with symptom duration of around 13 years. Twenty-five tofacitinib-treated patients (18.8%) were Asian.

Four different groupings of efficacy endpoints were evaluated, as well as safety data up to week 16 and then up to week 48. The study’s primary endpoint was an Assessment in Ankylosing Spondylitis (ASAS20) response achieved by week 16. An ASAS20 response is defined as an improvement of at least 20% and an absolute improvement from baseline of at least 20 units on a 0–100 scale in at least three of the following domains: patient global assessment of disease activity, pain assessment, physical function [Bath Ankylosing Spondylitis Functional Index] or inflammation; with no worsening in the remaining domain.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
At week 16, the study’s primary endpoint was met, with 56.4% of tofacitinib-treated patients achieving an ASAS20 response compared with only 29.4% of placebo-treated patients (P<0.0001). Additionally at week 16, a 40% improvement (ASAS40) was seen in 40.6% of tofacitinib-treated patients compared with 12.5% of placebo-treated patients (P<0.0001). Significant improvements were seen with tofacitinib compared with placebo in the other efficacy endpoints evaluated.

Serious and severe adverse events were reported in two tofacitinib-treated patients and placebo-treated patients. Three tofacitinib-treated patients and one placebo-treated patient discontinued treatment due to adverse events. Safety trends for the different dosages evaluated in this study were similar up to week 48.

In the tofacitinib-treated group, no deaths, deep vein thromboses, pulmonary emboli, arterial thromboemboli, gastrointestinal perforation, interstitial lung disease, major adverse cardiovascular events, malignancies, or opportunistic infections were reported up to week 48. Of these patients, one had an undefined hepatic event, one had meningitis and two had non-serious herpes zoster.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates

You Might Also Like:
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes
  • Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.